The LINKER-SMM1 trial shows promising results for linvoseltamab in treating high-risk smoldering multiple myeloma with a favorable safety profile, notes Paula Rodríguez-Otero, MD, PhD.
Paula Rodríguez-Otero, MD, PhD
Advertisement
Articles by Paula Rodríguez-Otero, MD, PhD
The LINKER-SMM1 trial evaluates linvoseltamab's safety and efficacy in high-risk smoldering multiple myeloma, aiming to delay disease progression.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Zanubrutinib Safe, Effective in Real-World CLL/SLL Cohort
2
Promises and Pitfalls of AI in Health Care
3
Paul Ryan Champions Health Care Policy Reform, AI Amid Government Shutdown
4
Review Outlines Shared Pathways Between CKD, VHD
5
